Endocrine Abstracts

Growth hormone replacement has not been recommended for use during pregnancy, due to lack of controlled trials to study its effects on the mother and the baby. We present a patient with hypopitiutarism on rhGH replacement which was continued during pregnancy with no adverse effects.A 35 years old lady, diagnosed ages 30 with pan-hypopituitarism secondary to non-functioning pituitary adenoma, she underwent trans-sphenoidal resection of the adenoma in 2002...

Nebido (testosterone undecanoate, 1000 mg) is a new, long acting, intramuscular (IM) preparation of testosterone (T) that can be administered every 10–14 weeks. We conducted a study to evaluate the factors that influence serum T levels after commencing Nebido and may therefore help clinicians estimate dosing frequency for this therapy.Following the recommended loading regimen, 51 hypogonadal men (35, 68.6% secondary hypogonadism) had two injections ...

It is important when initiating intramuscular Nebido (testosterone undecanoate) to monitor the serum testosterone level to ensure physiological replacement is achieved. Following a loading regimen of Nebido the manufacturer recommends measuring testosterone levels to determine the frequency of subsequent injections.We conducted a retrospective study of 36 hypogonadal men [12 (33%) primary hypogonadism, 24 (67%) secondary hypogonadism] to establish what f...

There are a number of symptomatic patients with hypothyroidism who fail to normalise thyroid function (TFTs) despite large doses of thyroxine (LT4) replacement. Non-compliance is a common cause of treatment failure even in patients who strongly deny this. To avoid unnecessary and prolonged investigations for other causes we advocate a simple protocol to manage this problem. Patients are observed taking 1000 mcg of LT4 at 09.00 hrs, and have hourly Free T4 and TSH levels measur...

Patients with GHD have an, adverse body composition, insulin resistance, atherogenic lipid profile and impaired quality of life. We undertook a single centre retrospective audit of hypopituitary adults to quantify the long-term effects of dose-titrated GH replacement.The cohort comprised 53 patients defined as severely GHD using the GST (median peak GH 2.4 μ/l). Mean age 42±16.9 years, 23F, BMI 29.3±5.3 kg/m2. GH was titrated un...